DARMSTADT, Germany, June 11, 2018 /PRNewswire/ — Primary endpoints met in two clinical trials for investigational targeted therapy, tepotinib, as a monotherapy in MET-positive, advanced hepatocellular carcinoma (HCC) with Child-Pugh Class A liver function These data provide further evidence of tepotinib activity in patients with MET-positive advanced cancers Given
Merck KGaA, Darmstadt, Germany Provides Update on Tepotinib Phase II Results in Advanced Hepatocellular Carcinoma
